Biomarkers and surrogate endpoints are key means to effect rational decisions during drug development and may be useful in general clinical practice and research as well. Recent advances in genomics and proteomics may increase the discovery of new biomarkers and their value in drug development. This special issue will review the use of surrogate endpoints and biomarkers in drug development, validation and qualification of biomarkers, pharmacogenomic biomarkers, and novel approaches to biomarker discovery, as well as discuss specific biomarkers including QTc prolongation and biomarkers of early stage cancer. The special issue will be of interest to researchers in academics, the pharmaceutical industry, and biotechnology.
Proceedings of the Joint Conference of the 67th Annual Meeting of the German Association of Medical Informatics, Biometry, and Epidemiology e.V. (gmds) and the 14th Annual Meeting of the TMF
